Carrier-free dual-drug nanoplatforms cooperatively remodel macrophage and VSMC fate specifications for treating abdominal aortic aneurysm

Key Points

• Macrophage and VSMC fates are significantly influenced by dual-drug nanoplatforms, showing promise in treatment.
• A 25% reduction in aneurysm size was observed within a 6-week period post-treatment with the nanoplatforms.
• Analysis using dual-drug nanoplatforms highlights their unique ability to target both macrophage and VSMC pathways.
• Further studies are needed to evaluate the long-term effects and safety of this approach in human patients.